These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32167250)

  • 1. [Targeted therapies for connective tissue diseases and vasculitis].
    Girard-Guyonvarc'h C; Iudici M
    Rev Med Suisse; 2020 Mar; 16(685):487-491. PubMed ID: 32167250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of connective tissue disease.
    Ciavaglia SJ; Costello PB; Panara N
    Ear Nose Throat J; 1987 Nov; 66(11):457-62. PubMed ID: 3443075
    [No Abstract]   [Full Text] [Related]  

  • 3. Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
    Justet A; Ottaviani S; Dieudé P; Taillé C
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of primary vasculitides with biologic and novel small molecule medications.
    Serling-Boyd N; Wallace ZS
    Curr Opin Rheumatol; 2021 Jan; 33(1):8-14. PubMed ID: 33164993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
    Pezot M; Nocturne G; Belkhir R; Henry J; Pavy S; Seror R; Mariette X; Bitoun S
    Ann Rheum Dis; 2024 Feb; 83(3):407-408. PubMed ID: 37945315
    [No Abstract]   [Full Text] [Related]  

  • 6. Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
    Muratore F; Pazzola G; Soriano A; Pipitone N; Croci S; Bonacini M; Boiardi L; Salvarani C
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):244-260. PubMed ID: 28895041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of corticosteroid agents in connective tissue disorders.
    Barraclough D
    Med J Aust; 1986 Apr; 144(8):427-32. PubMed ID: 2870416
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome.
    van den Hoogen LL; van Laar JM
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101485. PubMed ID: 32067925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone.
    Chevalier K; Belkhir R; Seror R; Mariette X; Nocturne G
    Ann Rheum Dis; 2020 Sep; 79(9):1257-1259. PubMed ID: 32398282
    [No Abstract]   [Full Text] [Related]  

  • 11. [Connective tissue diseases: news in therapy, role of biologics agents].
    Aubry-Rozier B; Fabreguet I
    Rev Med Suisse; 2013 Mar; 9(377):556, 558-60. PubMed ID: 23534242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases.
    Lamprecht P
    Autoimmun Rev; 2005 Jan; 4(1):28-34. PubMed ID: 15652776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of low-dose rituximab on hematological abnormalities in patients with connective tissue disease
.
    Wang CY; Guo SH; Wang LP; Wang XY; Shen HL
    Int J Clin Pharmacol Ther; 2019 Oct; 57(10):500-505. PubMed ID: 31426902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type II cryoglobulinaemic vasculitis with primary Sjögren's syndrome successfully treated with belimumab and hydroxychloroquine.
    Izuka S; Yamashita H; Takahashi Y; Kaneko H
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):223-224. PubMed ID: 33666157
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biologics for connective tissue diseases and vasculitides].
    Hellmich B; Henes JC
    Internist (Berl); 2022 Feb; 63(2):143-154. PubMed ID: 35029701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of collagen diseases.
    Calin A
    Ration Drug Ther; 1980 Jan; 14(1):1-5. PubMed ID: 7384531
    [No Abstract]   [Full Text] [Related]  

  • 18. Connective Tissue Disorder-Associated Vasculitis.
    Sharma A; Dhooria A; Aggarwal A; Rathi M; Chandran V
    Curr Rheumatol Rep; 2016 Jun; 18(6):31. PubMed ID: 27097818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential utility of B cell-directed biologic therapy in autoimmune diseases.
    Arkfeld DG
    Rheumatol Int; 2008 Jan; 28(3):205-15. PubMed ID: 17957371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryoglobulinemic vasculitis with primary Sjögren's syndrome: A case report.
    Hasegawa J; Hayami N; Hoshino J; Suwabe T; Sumida K; Mise K; Ueno T; Yamanouchi M; Sawa N; Ohashi K; Fujii T; Takaichi K; Ubara Y
    Mod Rheumatol; 2018 May; 28(3):570-574. PubMed ID: 26743943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.